Super jab for 15 cancers? Not quite, but it’s a time saver

You may have seen headlines this week about a new NHS “super jab” that can treat 15 cancers in five minutes. The phrasing alone is enough to get conspiracy theorists fizzing with excitement, but here’s what’s actually going on, without the drama.

The NHS has announced a faster way to administer an existing cancer immunotherapy, nivolumab (also known as Opdivo). The drug itself isn’t new. It’s already widely used to treat a range of cancers. The difference is that patients no longer need to sit for an hour-long IV drip. Instead, they’ll receive it as a quick injection under the skin, taking just three to five minutes.

This is called subcutaneous administration, and it’s now approved by the MHRA for eligible patients.

What cancers are we talking about?

The treatment is already licensed for use in 15 types of cancer, including:

Non-small cell lung cancer; Melanoma (skin cancer); Kidney cancer; Bladder cancer; Oesophageal cancer; Head and neck cancers; Liver cancer; Stomach cancer; Colorectal cancer; Cervical cancer; Uterine cancer; Hodgkin lymphoma; Mesothelioma; Bile duct cancer and certain rare cancers.

(Availability varies depending on NICE approvals and treatment stage.)

To be clear: this isn’t a vaccine

Despite the “super jab” label, this is not a vaccine and it doesn’t prevent cancer. It’s immunotherapy, a treatment that helps the body’s immune system recognise and fight cancer cells more effectively.

So no, it won’t be replacing chemotherapy or radiotherapy. And it definitely isn’t a miracle shot being rolled out to the general public.

Is this good news?

This change is a big win for patients, particularly those who are exhausted from repeated treatments. Shorter appointments mean less time in hospital and potentially fewer needles and cannulas for those who struggle with IV access.

From a system point of view, the NHS says it could benefit around 1,200 patients per month and free up precious time in treatment units. But will this mean more patients can be treated more quickly?

That’s less certain.

While in theory it could improve workflow, the actual bottlenecks in cancer treatment often lie elsewhere such as diagnostics, referrals, workforce shortages, and the availability of suitable drugs. In that context, shaving 45 minutes off an infusion is helpful, but it’s not a golden ticket to faster access.

Cost-wise, the NHS says the injection version comes at no extra cost, thanks to a commercial deal with the drug’s manufacturer. So, cost savings are minimal, but at least the change doesn’t come with a premium price tag.

Back to home